3 employees
Glialign is developing a novel cell therapy for peripheral nerve repair.
2017
Glialign raised undisclosed on May 4, 2018
Investors: UCL Technology Fund, Future Planet Capital, UK Innovation & Science Seed Fund and Innovate UK